Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration

ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

Optical coherence tomography will be in all eye care services by October 2025